- Czech Republic, Sweden, Poland and Norway authorities give green light to start the Phase III clinical studies on their territories.
- The progress of the clinical program regarding the Estetrol-based contraceptive product candidate is in line with objectives and remains on schedule.
- In parallel, the MIT-ES001-C302 study will be conducted in the United States and in Canada.
- Mithra set up an International European Advisory Board about the development of its Estetrol-based contraceptive product candidate to meet market needs.
Liège, Belgium 24 March 2016 – On the 9 countries selected to host Phase III clinical trials for Mithra’s contraceptive product candidate based on Estetrol (Estelle®) in Europe, 4 already fully approved the clinical trials protocol. Competent Authorities and Central Ethic Committees of Czech Republic, Sweden, Poland and Norway gave their green light to start the final study of one of Mithra’s lead R&D projects on their territory.